Subscribe

Radiopharm Theranostics Limited (RAD.AX)

AUD0.02 +0.00 (+0.00%)
AU ASX Healthcare Biotechnology
Address 62 Lygon Street 3053
Carlton, VIC, AU
CEO Riccardo Canevari
Website radiopharmtheranostics.com
IPO 2021-11-25
ISIN AU0000181851

Explore sections of this company profile

Also trades on Australian Securities Exchange · RAD.AX (AUD) NASDAQ Capital Market · RADX (USD)
Description

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
AUD0.02 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.80
Float Shares
2.37B
Free Float %
100.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-4.76% +0.00% +5.26% -13.04% -9.09% -20.00% -28.57% -83.98% -94.39% -94.39% -94.39%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.02
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-4.47
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +4,378.3% ★ Q4'25: -65.9% (vs Q4'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    +85.3% ★ Q4'25: +89.5% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -281.8% Q4'25: -1,636.3% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -255.5% Q4'25: -2,245.0% (vs Q4'23)
  • ✗
    ROIC Biotechnology: -16.1%
    -248.9% Q4'25: -697.6% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +439.6% Q4'25: +932.4% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.78) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.02
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jun 2023
actual 		Jun 2024
actual 		Jun 2025
actual 		Jun 2026
6 Rev. Ana.
1 EPS Ana. 		Jun 2027
5 Rev. Ana.
2 EPS Ana. 		Jun 2028
4 Rev. Ana.
2 EPS Ana. 		Jun 2029
2 Rev. Ana.
1 EPS Ana. 		Jun 2030
2 Rev. Ana.
1 EPS Ana.
Revenue
292.4K
est: 300.0K (-2.5%)
299.2K
est: 299.0K (+0.1%)
13.40M
est: 1.27M (+959.0%)
2.25M
2.25M – 2.25M
+77.8% YoY
2.33M
2.33M – 2.33M
+3.7% YoY
34.11M
34.11M – 34.11M
+1,362.3% YoY
119.00M
119.00M – 119.00M
+248.8% YoY
186.33M
186.33M – 186.33M
+56.6% YoY
EBITDA
-37.11M
est: -180.0K (-20,515.6%)
-45.38M
est: -179.4K (-25,193.3%)
-31.65M
est: -759.2K (-4,068.2%)
-1.35M
-1.35M – -1.35M
-77.8% YoY
-1.40M
-1.40M – -1.40M
-3.7% YoY
-20.47M
-20.47M – -20.47M
-1,362.3% YoY
-71.40M
-71.40M – -71.40M
-248.8% YoY
-111.80M
-111.80M – -111.80M
-56.6% YoY
EBIT
-40.40M
est: -180.0K (-22,347.0%)
-48.50M
est: -179.4K (-26,935.9%)
-34.24M
est: -759.2K (-4,410.1%)
-1.35M
-1.35M – -1.35M
-77.8% YoY
-1.40M
-1.40M – -1.40M
-3.7% YoY
-20.47M
-20.47M – -20.47M
-1,362.3% YoY
-71.40M
-71.40M – -71.40M
-248.8% YoY
-111.80M
-111.80M – -111.80M
-56.6% YoY
Net Income
-34.61M
est: -167.41M (+79.3%)
-47.95M
est: -213.01M (+77.5%)
-36.70M
est: -49.09M (+25.2%)
-34.49M
-34.49M – -34.49M
+29.7% YoY
-36.02M
-40.93M – -31.11M
-4.4% YoY
-22.83M
-44.21M – 4.17M
+36.6% YoY
-2.14M
-2.14M – -2.14M
+90.6% YoY
18.36M
18.36M – 18.36M
+956.3% YoY
SGA
15.26M
est: 90.83M (-83.2%)
15.22M
est: 90.53M (-83.2%)
16.53M
est: 383.12M (-95.7%)
681.21M
681.21M – 681.21M
+77.8% YoY
706.34M
706.34M – 706.34M
+3.7% YoY
10.33B
10.33B – 10.33B
+1,362.3% YoY
36.03B
36.03B – 36.03B
+248.8% YoY
56.41B
56.41B – 56.41B
+56.6% YoY
EPS
-0.11
est: -0.08 (-37.0%)
-0.12
est: -0.11 (-9.1%)
-0.02
est: -0.02 (+24.4%)
-0.02
-0.02 – -0.02
+28.9% YoY
-0.02
-0.02 – -0.01
-4.4% YoY
-0.01
-0.02 – 0.00
+44.4% YoY
0.00
0.00 – 0.00
+89.3% YoY
0.01
0.01 – 0.01
+956.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-28 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-27 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-26 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-25 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-22 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-21 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-20 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-19 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-18 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-15 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-13 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-12 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-05-11 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-05-08 C 2/5 2/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C 2/5 2/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C 2/5 2/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C 2/5 2/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C 2/5 2/5 1/5 1/5 1/5 1/5 4/5
2026-05-01 C 2/5 2/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C 2/5 2/5 1/5 1/5 1/5 1/5 4/5
2026-04-29 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C- 1/5 2/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-70.33M
OE per share TTM
-0.10
Owner's Yield
-99.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-24.5K
Shares Outstanding
2.36B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Riccardo Canevari MD, Chief Executive Officer & Director 2M male
Dimitris Voliotis Chief Medical Officer 1M —
Paul Edward-Alexander Hopper FAICD Founder & Executive Chairman 317.7K male
Aaron Laurita Chief Financial Officer — male
Phillip Hains CFO & Joint Company Secretary — male
Nathan Jong Joint Company Secretary — male
Amritha Sushil Joint Company Secretary — female
Hitesh Goel Head of Project Management — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology